文献速递腹部技术与安全MR

单次或多次应用钆基对比剂后患者肝组织中钆沉积的定量分析

Quantitative Analysis of Gadolinium Deposits in Liver Tissue of Patients After Single or Multiple Gadolinium-based Contrast Agent Application.
PubMed 文献 · Invest Radiol · 2026-08-01

该研究对25例接受过1至9次钆基对比剂(GBCA)后行肝肿瘤切除术的患者肝标本,用ICP-MS定量分析钆质量分数并评估组织学特征。钆中位质量分数为0.348 µg/g,与炎症和纤维化评分无显著相关,与末次给药至手术时间(对数)呈强负相关,与给药次数正相关而与累积剂量无关。

要点

  • 肝标本钆中位质量分数0.348 µg/g(范围0.120–0.874 µg/g),所有样本均可检出。
  • 钆质量分数与末次给药至手术间隔(对数)呈强负相关(P < 0.001)。
  • 钆质量分数与GBCA给药次数正相关(P = 0.010),与累积剂量无关(P = 0.205)。

核心结论

  • 静脉给予GBCA后,小部分钆在肝脏中滞留至少数周。
  • 钆滞留与GBCA给药次数相关,而与累积剂量及脂肪肝病程度无关。
  • 钆质量分数与包括炎症和纤维化在内的组织学评分无显著相关。

研究设计与样本

  • 经机构审查委员会批准的研究,对25例接受过GBCA(4年内1至9次)并因肝肿瘤行切除术的受试者肝标本进行定量分析。
  • 采用电感耦合等离子体质谱(ICP-MS)定量分析人肝标本中钆的质量分数ω(Gd)。
  • 基于非酒精性脂肪性肝病活动度评分(NAS)评估组织形态学。
  • 对ω(Gd)、时间和剂量指标及组织病理学参数进行线性回归分析。

关键影像表现/征象

  • 所有肝样本中均检测到钆。
  • 钆质量分数中位数为0.348 µg/g(范围:0.120至0.874 µg/g)。

诊断标准与关键数值

  • 末次GBCA给药至手术的中位间隔T为14天(范围:1至69天)。
  • 钆质量分数ω(Gd)中位数为0.348 µg/g(范围:0.120至0.874 µg/g)。
  • ω(Gd)与ln(T)呈强负相关(P < 0.001)。
  • ω(Gd)与既往GBCA给药次数呈正相关(P = 0.010),与累积剂量无显著相关(P = 0.205)。
  • ω(Gd)与组织学评分(包括炎症和纤维化)无显著相关。

临床应用与阅片要点

  • 原文未据此给出推荐。
  • 结果提示静脉给予GBCA后小部分钆在肝脏中滞留至少数周。
  • 观察到钆滞留与GBCA给药次数相关,而与累积剂量及脂肪肝病程度无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Gadolinium-based contrast agents (GBCAs) are widely used in magnetic resonance imaging. Concerns exist regarding gadolinium deposition and its potential histopathologic tissue alterations, especially after repeated administrations of linear, less stable GBCAs. This study aimed to quantify gadolinium mass fractions in liver specimens of subjects exposed to GBCAs in correlation with histopathologic features.

MATERIALS AND METHODS: In this Institutional Review Board-approved study, mass fractions of gadolinium in human liver specimens ω(Gd) from 25 subjects who underwent liver tumor resection surgery and had received GBCA (1 to 9 times over 4 y), were quantitatively analyzed using inductively coupled plasma-mass spectrometry (ICP-MS). Histomorphology was assessed based on the nonalcoholic fatty liver disease activity score (NAS). Linear regression analyses were performed with ω(Gd), time and dosage metrics, and histopathologic parameters.

RESULTS: The median interval between last GBCA administration and surgery (T) was 14 days (range: 1 to 69 d). Gadolinium was detected in all liver samples (ω(Gd), median: 0.348 µg/g; range: 0.120 to 0.874 µg/g). No significant correlation was found between ω(Gd) and histologic scores, including inflammation and fibrosis. A strong negative correlation was found between ω(Gd) and ln(T) ( P < 0.001). A positive correlation existed between ω(Gd) and the number ( P = 0.010) but not the cumulative dose of previous GBCA administrations ( P = 0.205).

CONCLUSIONS: Our results suggest that after intravenous administration of GBCA, a small fraction of gadolinium is retained in the liver over a time period of at least several weeks. A relationship was observed between Gadolinium retention and the number of GBCA administrations, but not with the cumulative dose and the degree of fatty liver disease.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Bayerl C, Shahryari M, Reiter R, et al. Quantitative Analysis of Gadolinium Deposits in Liver Tissue of Patients After Single or Multiple Gadolinium-based Contrast Agent Application. Invest Radiol. 2026. PMID: 41216759. doi:10.1097/RLI.0000000000001254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。